A5055125756- Research on Leishmaniasis Studies
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Trypanosoma species research and implications
- Immunotherapy and Immune Responses
- Heart rate and cardiovascular health
- Vector-borne infectious diseases
- T-cell and Retrovirus Studies
- Veterinary medicine and infectious diseases
- Heart Rate Variability and Autonomic Control
- Vector-Borne Animal Diseases
- Antimicrobial Peptides and Activities
- Parasites and Host Interactions
Universidade Federal de Ouro Preto
2020-2024
Many vaccine candidates against visceral leishmaniasis (VL) have been proposed; however, to date, none of them efficacious for the human or canine disease. On this basis, design vaccines has constantly changing, and use approaches select specific epitopes seems be crucial in scenario. The ability predict T cell-specific makes immunoinformatics an even more necessary approach, as VL efficient immune response parasite is triggered by lymphocytes Leishmania spp. immunogenic antigens. Moreover,...
Diagnosing canine visceral leishmaniasis (CVL) in Brazil faces challenges due to the limitations regarding sensitivity and specificity of current diagnostic protocol. Therefore, it is urgent map new antigens or enhance existing ones for future techniques. Immunoinformatic tools are promising identification potential epitopes antigen candidates. In this study, we evaluated peptides selected by epitope prediction CVL serodiagnosis ELISA assays. Ten B-cell were immunogenic silico, but two...
Background: The adjuvants’ optimal dose and the administration route can directly influence epitope recognition patterns profiles of innate response. We aimed to establish effect adjuvant systems for proposing a vaccine candidate be employed with Leishmania (Viannia) braziliensis. Methods: evaluated adjuvants saponin (SAP), monophosphoryl lipid A (MPL) resiquimod (R-848) isolated combined as in lower corresponding 25%, 33%, 50% each total dose. Male outbred BALB/c mice were divided into 13...
Adjuvants act in the innate immunity and, when combined to vaccine antigens, can produce a more intense response, improving antigen presentation, directing immune system, excellent for new formulations.